Posted by Michael Wonder on 16 Oct 2017
Cancer drug study data was falsified, says AstraZeneca
14 October 2017 - An early lab study supporting a cancer drug bought by British drugmaker AstraZeneca was falsified, the company has admitted.
AstraZeneca bought a majority stake in US rival Acerta Pharma at the end of 2015 for $4bn (£3bn) on the strength of its novel drug acalabrutinib under development for treating blood cancers and solid tumours. More than 2,000 patients are taking part in more than 25 acalabrutinib clinical trials.
Last month Acerta retracted an abstract, published in medical journal Cancer Research in August 2015 – four months before the AstraZeneca investment – purportedly showing the drug was effective in treating solid tumours in mice.
